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ABSTRACT
The expression of cPLA2 is critical for transformed
growth of non-small cell lung cancer (NSCLC). It is
known that phorbol 12-myristate 13-acetate (PMA)-
activated signal transduction pathway is thought to
be involved in the oncogene action in NSCLC and
enzymatic activation of cPLA2. However, the tran-
scriptional regulation of cPLA2a in PMA-activated
NSCLC is not clear. In this study, we found that PMA
induced the mRNA level and protein expression
of cPLA2a. In addition, two Sp1-binding sites of
cPLA2a promoter were required for response to
PMA and c-Jun overexpression. Small interfering
RNA (siRNA) of c-Jun and nucleolin inhibited PMA
induced the promoter activity and protein expres-
sion of cPLA2a. Furthermore, PMA stimulated the
formation of c-Jun/Sp1 and c-Jun/nucleolin com-
plexes as well as the binding of these transcription
factor complexes to the cPLA2a promoter. Although
Sp1-binding sites were required for the bindings of
Sp1 and nucleolin to the promoter, the binding of
nucleolin or Sp1 to the promoter was independent
of each other. Our results revealed that c-Jun/
nucleolin and c-Jun/Sp1 complexes play an impor-
tant role in PMA-regulated cPLA2a gene expression.
It is likely that nucleolin binding at place of Sp1 on
gene promoter could also mediate the regulation
of c-Jun/Sp1-activated genes.
INTRODUCTION
The production of lipid mediators, the eicosanoids
(i.e. prostaglandins and leukotrienes) are derived from
metabolism of arachidonic acid, which has been impli-
cated in the regulation of cell growth, inﬂammation,
thrombosis and tumor progression (1–3). There is much
evidence indicating that eicosanoids, particularly prosta-
glandins, are involved in the etiologies of cancer (4).
Increased levels of eicosanoids occur in a number of
diﬀerent types of human cancer, including colon, pan-
creatic, breast and lung. In the case of lung cancer,
increased prostaglandin biosynthesis has been found to
occur mainly in non-small cell lung cancer (NSCLC),
which comprises 80% of lung cancers rather than small
cell lung cancer (SCLC) (5,6). In addition, the increase of
cPLA2 is correlated with the eicosanoid synthesis that
participates in NSCLC transformation (7).
Cytosolic phospholipase A2 (cPLA2) is the major
intracellular form of PLA2, which preferentially hydro-
lyzes membrane phospholipids at the sn-2 position to
release arachidonic acid (8). cPLA2 activity is regulated by
intracellular Ca
2+ and phosphorylation. Increase in Ca
2+
results in translocation of cPLA2 to the nuclear envelope
and activation (9,10). But it has been shown that phorbol
12-myristate 13-acetate (PMA) provides cPLA2-activating
signals without inducing Ca
2+ inﬂux (11,12) and by a
Rac-p38 kinase-dependent pathway (13). The maximal
activation of cPLA2 requires sustained phosphorylation of
Ser505, Ser727 and Ser515 by mitogen-activated protein
kinases (MAPKs), MAPK-activated protein kinases and
by calcium/calmodulin-dependent protein kinase II,
respectively (14–16). In addition to acute regulation,
expression of cPLA2 through changes in gene transcrip-
tion is mediated by a number of agents including
cytokines, thrombin and growth factors (17–21). The
promoter for cPLA2 has been isolated from both human
(18) and rat (22). A number of putative binding sites for
possible regulatory elements have been identiﬁed within
the promoter, including AP-1 sites, nuclear factor kB sites
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2.4kb region of the promoter fragment down to the last
58bp of the 50-untranslated region has been identiﬁed in
three regulatory regions and indicates that the transcrip-
tion factor Sp1 can bind to two of these regions (23,24).
In the regulation of cPLA2 promoter, LKLF (lung
Kru ¨ ppel-like factor) as a transcriptional activator also
binds to the cPLA2 promoter and may interact with the
Sp1 family (25).
Although Sp1 is required for the transcriptional activa-
tion of cPLA2 gene, only a limited number of studies have
addressed the mechanisms by which cPLA2 gene expres-
sion is controlled. In addition to enzymatic activation,
in this study, we also clariﬁed that PMA could activate
the transcription via the Sp1-binding sites of cPLA2a
promoter in NSCLC A549 cells. We demonstrated that
transcription factors c-Jun and Sp1 form a complex to
regulate PMA-induced gene expression of cPLA2a as the
manner as the c-Jun/Sp1-regulated genes including 12(S)-
lipoxygenase, keratin 16, p21
WAF1/CIP1 and neuronal
nicotinic acetylcholine receptor b4 (26–29). We further
performed pull-down and protein–DNA interaction
assays to show that nucleolin bound to DNA and
activated transcription of cPLA2a in PMA-treated cells.
Nucleolin is reported to be a ubiquitously expressed
multifunctional protein involved in ribosomal biogenesis
and the regulation of nucleolar translocation of ribosomal
proteins (30). Functional role of nucleolin in the activa-
tion and repression of gene transcription as well as in the
regulation of RNA metabolism has already been reported
(31). Our results revealed a new function for nucleolin as a
c-Jun/Sp1-interacting partner and transcription activator
in PMA-induced gene expression of cPLA2a.
MATERIALS AND METHODS
Cellculture
Human epidermoid carcinoma A431 and NSCLC A549
cells were grown at 378C under 5% CO2 in 10cm plastic
dishes containing 10ml of Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen-GIBCO) and nutrition mixture F12
Kaighn’s modiﬁcation medium (Biowest), respectively and
supplemented with 10% fetal bovine serum, 100mg/ml
streptomycin and 100U/ml penicillin. In this series of
experiments, cells were treated with 5nM PMA (Sigma, St
Louis, MO) in culture medium supplemented with 10%
fetal bovine serum, unless stated otherwise.
Reverse transcription-PCR (RT-PCR)
Total RNA was isolated using the TRIzol RNA extraction
kit (Invitrogen, Grand Island, NY), and 5mg of RNA
were subjected to RT-PCR with SuperScript
TMII
(Invitrogen, Grand Island, NY, USA). The cPLA2a-
speciﬁc primers (sense, 50-CTG ATG TTT GCA GAT
TGG GTT G-30; antisense, 50-AAA GGA GAC AGT
GGA TAA GAT G-30), nucleolin-speciﬁc primers (sense,
50- AGA AGG GAG CCA CAC CAG GC-30; antisense,
50- AGC TGC TGC TTT CAT CGC TG-30) and GAPDH
primers were used. The PCR products were separated by
1% agarose-gel electrophoresis and visualized with
ethidium bromide staining.
Northern blot analysis
Total RNA was isolated using the TRIzol RNA extraction
kit (Invitrogen, Grand Island, NY), and 20mg of RNA
were used for electrophoresis and transferred to a nylon
membrane as previously described (32). The cDNA probes
used were prepared from RT-PCR. Probes were labeled
with [a-
32P]dCTP by using a Rediprime
TMII random
prime labeling system (Amershan, Bucks, UK). The nylon
membranes were washed three times at room temperature
in 2  standard saline/phosphate/EDTA buﬀer (300mM
NaCl, 20mM NaH2PO4 and 2mM EDTA) containing
0.1% SDS. Each wash was carried out for 15min.
Autoradiography was then performed.
Plasmid construction
A 619bp of human cPLA2a promoter region was PCR-
ampliﬁed from human genomic DNA and subcloned into
luciferase plasmid pXP1 as the pPLA599 plasmid.
Respective additions of KpnI to forward primer 50-GA
AATTCAAACCTGAATTCAATTTTCTTCCCT-30 and
of HindIII to reverse primer 50-GATCCTTTTTCAGC
TCCGGA-30 facilitated subcloning. 50-Deletions of var-
ious lengths, pPLA393, pPLA241, pPLA140, pPLA53,
pPLA35 and pPLA27 were generated using reverse primer
50-GATCCTTTTTCAGCTCCGGA-30 and the forward
primers 50-AACTTTGCCTTTTTAAATAATGCA-30,
50-ACAGAAATCCGCAACAGCACTC-30,5 0-CATTTA
CATTTACAATATTAGC-30,5 0-GGAGACCAGCCCA
CATTTTAG-30,5 0-TAGCCCCTCCTACTCAGG-30 and
50-CCTACTCAGGATAAGACT-30, respectively. The
mutants at Sp1 site (pLAm) were constructed by the
site-directed mutagenesis method. Synthetic primers were
shown in the following: pLAm1 mutant primer 50-G G
AGACCAGTTCACATTTTAG -30, and pLAm2 mutant
primer 50- TAGTTCTTCCTACTCAGG -30. Mutated
positions in the sequence of the primers were underlined.
All DNA fragments were directly subcloned into pXP1
using KpnI and HindIII. The vector sequence was
conﬁrmed by DNA sequencing. To generate the luciferase
plasmid UTR-1-446, a 447bp of human cPLA2a mRNA
30UTR was PCR-ampliﬁed from cDNA and inserted
between luciferase gene and SV40 late poly(A) signal
coding regions of luciferase plasmid pGL3. Respective
additions of XbaI to forward primer 50-TTCATG
TACTGGAAATGGCAGC-30 and of FseI to reverse
primer 50-CATGTATGTATATATATGC-30 facilitated
subcloning. The nucleotide sequences of constructs were
conﬁrmed by automatic DNA sequencing.
Transfection ofcells with plasmids
Cells were transfected with plasmids by lipofection using
Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA)
according to the manufacturer’s instruction with a slight
modiﬁcation. Cells were replated 24h before transfection
at an optimal cell density in 2ml of fresh culture medium
in a 3.5cm plastic dish. For use in transfection, 0.5 mlo f
Lipofectamine 2000 was incubated with 0.5mg of pPLA,
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of cyclooxygenase-2 (34) luciferase plasmid or the
indicated plasmids as described in each experiment, in
1ml of Opti-MEM medium for 30min at room tempera-
ture. Total DNA concentration for each transfection was
normalized with pcDNA3.1. Cells were transfected by
changing the medium with 1ml of Opti-MEM medium
containing the plasmids and Lipofectamine 2000, followed
by incubation at 378C in a humidiﬁed atmosphere of 5%
CO2 for 24h. After a change of Opti-MEM medium to
2ml of fresh culture medium, cells were stimulated with
PMA if necessary and then incubated for an additional
18h, unless stated otherwise. The luciferase activity in cell
lysate was determined as described previously (33).
DNA affinity precipitation assay(DAPA)
This assay was performed according to the method
reported previously (35) with a slight modiﬁcation. The
binding assay was performed by mixing 200mg of nuclear
extract proteins, 2mg of biotinylated speciﬁc wild-type and
mutated Sp1 oligonucleotides of cPLA2a, 12(S)-lipoxy-
genase and gastrin promoters 50-CAA GGA GAC CAG
CCC ACA TTT TAG CCC CTC CTA CTC AGG-30,
50-CAA GGA GAC CAG CTT ACA TTT TAT CCC
TTC CTA CTC AGG-30,5 0- TAA AAC TTG CGA GGA
GGG CGG GGC CGC AG-30 and 50-CAG GGT AGG
GGC GGG GTG GGG GGA CA-30, respectively, and
Sp1 and NFkB consensus oligonucleotides 50-ATT CGA
TCG GGG CGG GGC GAG C-30 and 50-AGT TGA
GGG GAC TTT CCC AGG C-30, respectively, and 20 ml
of streptavidin-agarose beads (4%) with 50% slurry.
Mutated positions in the sequence were underlined. The
mixture was incubated at room temperature for 1h with
rotating. Beads were pelleted and washed three times with
PBS. The binding proteins were eluted by loading buﬀer
and separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE), followed by western
blot analysis probed with speciﬁc antibodies.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assay was done accord-
ing to previous report (36) with minor modiﬁcation.
Brieﬂy, A549 cells were treated with 1% formaldehyde
for 15min. The cross-linked chromatin was sonicated
to 400–500bp fragments. Lysates were precleared with
protein A beads and incubated overnight at 48C with
antibodies speciﬁc to nucleolin (Santa Cruz Biotechology,
Santa Cruz, CA, USA), c-Jun (Santa Cruz, CA, USA) and
Sp1 (Santa Cruz, CA, USA). Immune complex was
precipitated with protein A beads preabsorbed with
sonicated salmon sperm DNA and BSA. After reversal
of cross-linking, levels of precipitated cPLA2a promoter
DNA were determined by PCR using oligonucleotides
spanning the Sp1-binding sites (sense, 50-ACA GAA ATC
CGC AAC AGC ACT C-30; antisense, 50-GAT CCT TTT
TCA GCT CCG GA-30). The PCR products were
separated by 1% agarose-gel electrophoresis and visual-
ized with ethidium bromide staining.
Westernblotting
The cytoplasmic fractions and nuclear extracts of cells
were prepared for western blot analysis according to the
method described (37). An analytical 10% SDS–PAGE
was performed, and 30mg of protein of each sample were
analyzed, unless stated otherwise. For immunoblotting,
proteins in the SDS gels were transferred to a polyviny-
lidene diﬂuoride membrane by an electroblot apparatus.
Antibodies against human Sp1 (Santa Cruz, CA, USA),
c-Jun (Santa Cruz, CA, USA), nucleolin (Santa Cruz, CA,
USA) and b-actin (Santa Cruz, CA, USA) were used as
the primary antibodies. Mouse or rabbit IgG antibodies
coupled to horseradish peroxidase were used as secondary
antibodies. An enhanced chemiluminescence kit (Pierce,
Rockford, IL, USA) was used for detection.
Coimmunoprecipitation
Two hundred micrograms protein of nuclear extracts
and lysate were incubated under gentle shaking at 48C
overnight with a mixture of anti-c-Jun or anti-Sp1
antibodies and protein A agarose in 300ml of immuno-
precipitation buﬀer [20mM HEPES, pH 7.9, 420mM
NaCl, 1.5mM MgCl2 and 25% glycerol (v/v), 0.5mM
phenylmethylsulfonyl ﬂuoride, 1mM orthovanadate,
2mg/ml pepstatin A and 2mg/ml leupeptin]. Beads were
pelleted at 7500g for 2min and washed three times with
RIPA buﬀer [50mM Tris–HCl, pH 7.5, 1% IGEPAL CA-
630 (v/v), 150mM NaCl, and 0.5% sodium deoxycholate].
Protein was removed from the beads by boiling in sample
buﬀer (120mM Tris–HCl, pH 6.8, 10% glycerol, 3% SDS,
20mM DTT, and 0.4% bromophenol blue) for 5min and
subjected to 10% SDS–PAGE. Western blot analysis was
carried out as described above.
RESULTS
Effectof PMA onthe transcription ofcPLA2agene
Expression of cPLA2a was detected by northern blot and
immunoblot analysis in PMA-treated A549 cells. PMA
induced the expression of cPLA2a mRNA (Figure 1A)
and protein (Figure 1B) in a time-dependent manner. To
conﬁrm that PMA enhanced the expression of cPLA2a
through the transcriptional activation of the gene, the
vector containing human cPLA2a gene promoter was used
in the reporter assay. PMA induced the promoter activity
of cPLA2a in a time-dependent manner (Figure 2A). The
maximum eﬀect of PMA on the promoter activity was
observed in cells treated with PMA for 18h. To identify
the promoter elements responsible for PMA induction,
DNA constructs with 50-deletions of cPLA2a promoter
were transiently transfected into cells. The eﬀect of PMA
on the luciferase reporter activity was then studied and
summarized in Figure 2B. The luciferase activities of
vectors pPLA 599, pPLA 393, pPLA 241, pPLA 140 and
pPLA 53 were stimulated by PMA treatment. The
stimulation was about 5-fold, obtained by comparing
the luciferase activity in PMA-treated cells with that in
control cells. An apparent decrease in the stimulatory
response of PMA was observed in vectors bearing a
Nucleic Acids Research,2008, Vol. 36,No. 1 219promoter with a deletion from  53 (pPLA 53) to  27bp
(pPLA 27), indicating that a promoter region ranging
from  53 to  27bp was required for the PMA-induced
expression of cPLA2a. To further conﬁrm whether two
Sp1-binding sites ( 45 to  42bp and  33 to  29bp)
located in the region were important for PMA response,
DNA constructs with mutations on Sp1-binding sites were
transfected into cells. Compared to pPLA599, a signiﬁcant
decrease in PMA-stimulated response was observed in
pPLA m1 and pPLA m2, and a complete elimination of
PMA response was detected in pPLA m1/2. In addition,
overexpression of Sp1 also induced the promoter activity
of cPLA2a (Figure 2C). These results indicated that two
Sp1 sites were essential for PMA-induced transcriptional
activation of cPLA2a gene and Sp1 was involved in the
regulation of gene expression.
Effectof c-Jun/Sp1 on thePMA-induced transcriptional
activationof cPLA2agene
Since overexpressing Ha-Ras leads to induction of c-Jun
protein and drives rat cPLA2a promoter activity (23), we
then studied the possibility that whether c-Jun also
cooperated with Sp1 in the regulation of PMA-induced
expression of human cPLA2a gene. To conﬁrm the role of
c-Jun in PMA-regulated gene expression, c-Jun siRNA
oligonucleotides were transfected into cells. As shown
in Figure 3A, c-Jun siRNA inhibited PMA-induced
promoter activity and protein expression of cPLA2a.
Furthermore, overexpression of c-Jun also induced the
promoter activity of cPLA2a gene (Figure 3B). Consistent
with the results of Figure 2B, the luciferase activity of
vectors pPLA 599, pPLA 393, pPLA 241, pPLA 140 and
pPLA 53 but not pPLA 35 and pPLA 27 were stimulated
by pRSVjun (Figure 3B). A signiﬁcant decrease in
pRSVjun response was observed in pPLA m1 and pPLA
m2, whereas the response was completely abolished in
pPLA m1/2. These results indicated that the two Sp1 sites
play an important role in c-Jun-induced transcription of
cPLA2a gene as well as the PMA response (Figure 2B).
Since there is no AP1 site within the promoter region
ranging from  53 to  27bp, we therefore speculated that
the eﬀect of c-Jun on gene expression was mediated by
cooperation with Sp1.
We then studied the functional interaction between
c-Jun and Sp1 in the regulation of PMA-induced gene
expression of cPLA2a by immunoprecipitation, DAPA
and ChIP assay. Expression of Sp1 and c-Jun in nuclear
extracts prepared from cells treated with PMA for 1–6h
was studied by using immunoblot analysis. No diﬀerence
of Sp1 expression between control and PMA-treated cells
was observed (Figure 4A). PMA induced the expression of
c-Jun (Figure 4A), and enhanced the interaction between
c-Jun and Sp1 (Figure 4B). To directly examine whether
the c-Jun/Sp1 complex bound to cPLA2 a promoter in
PMA-treated cells, the probes containing two Sp1-binding
sites of cPLA2a promoter were used in DAPA. The
binding of c-Jun and phospho-c-Jun but not Sp1 to the
promoter under the PMA stimulation was increased
(Figure 4D and E). In addition, phospho-c-Jun binding
to the promoter was signiﬁcantly increased by over-
expressed Sp1 in cells (Figure 2C). In ChIP assay, the
binding of c-Jun but not Sp1 to the promoter in cells
under the PMA treatment was also enhanced (Figure 4F).
These results suggested that PMA induced the formation
of c-Jun/Sp1 complex, resulting in facilitating the access
of activated c-Jun to the promoter and enhanced the
transcriptional activation.
Nucleolin mediates thePMA-induced transcriptional
activation ofcPLA2agene
To gain insight into the PMA-regulated transcriptional
mechanism of cPLA2a gene, factors bound to Sp1 sties of
cPLA2a promoter were analyzed by DAPA. The bound
proteins were subsequently analyzed by 2D SDS–PAGE.
Proteins on the gel were identiﬁed by MALDI-TOF. One
of the proteins, nucleolin bound to the probe was then
clearly identiﬁed (data not shown). As shown in Figure 4D
analyzed by DAPA, the binding of nucleolin to the
promoter was not changed in PMA-treated cells as well as
Sp1 binding. In addition, the constant interaction between
nucelolin and Sp1 was observed in control or PMA-
treated cells (Figure 4C). However, the interaction of
nucleolin with c-Jun was increased in PMA-treated
condition (Figure 4C). We further conﬁrmed the binding
of nucleolin to cPLA2a promoter by ChIP assay
(Figure 4F), which was consistent with the results shown
in Figure 4D. Since the formation and binding of c-Jun/
nucleolin complex to cPLA2a promoter was increased in
PMA-treated cells, it is likely that nucleolin is involved in
the regulation of PMA-induced cPLA2a gene expression.
We then studied the role of nucleolin in the regulation of
PMA-induced gene expression. As shown in Figure 5A,
PMA-induced promoter activity and protein expression of
cPLA2a were inhibited in nucleolin knockdown cells.
Nucleolin siRNA oligonucleotides also signiﬁcantly inhib-
ited the PMA-induced increase of cPLA2a mRNA
(Figure 5B). These results revealed that c-Jun/nucleolin
complex played an important role in PMA-induced
cPLA2a
GAPDH
PMA(5 nM)     −
−− −−
−−− + + + +
Time (h) 1 1 3 3 6 6 12 12
PMA(5 nM)      + + + +
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cPLA2b
b-actin
A
B
Figure 1. PMA induces the expression of cPLA2a in A549 cells.
(A) A549 cells were starved for 18h in serum-free culture medium and
then treated with 5nM PMA for a diﬀerent time period as indicated.
Northern blot analysis of mRNA was performed. (B) Cell lysates were
subjected to SDS–PAGE and analyzed by western blotting with
antibodies against cPLA2a and b-actin.
220 Nucleic Acids Research, 2008, Vol. 36, No. 1cPLA2a gene expression. Tay et al. (38) have shown that
epidermal growth factor, platelet-derived growth factor,
serum and PMA exert their eﬀects on cPLA2 expression
through post-translational mechanisms involving stabili-
zation of the mRNA. In order to conﬁrm that whether
nucleolin-regulated PMA-induced cPLA2a gene expres-
sion through transcriptional activation pathway,
pGL3 vector containing SV40 promoter and luciferase
cDNA without cPLA2a promoter was used. The
sequence of SV40 promoter was analyzed by the computer
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Figure 2. Analysis of PMA-responsive element in the promoter region of cPLA2a gene in A549 cells. (A) Cells were transfected with 0.5mgo f
luciferase plasmid bearing cPLA2a gene promoter by lipofection, incubated for 24h and then treated with 5nM PMA for a diﬀerent time period as
indicated. The luciferase activities and protein concentrations were determined and normalized. The results shown represent the means SEM of
three determinations. Blank columns: non-treatment; black columns: PMA-treated cells. (B) Truncated promoter fragment was ligated into a
luciferase plasmid as described in the Materials and Methods section. Numbers indicate the distance in base pairs from the translation start site. Cells
were transfected with 0.5mg of luciferase plasmid bearing cPLA2a gene promoter by lipofection, incubated for 24h and then treated with 5nM PMA
for 18h. The luciferase activities and protein concentrations were determined and normalized. The expression ratio of PMA treated to control cells is
indicated. The results shown represent the means SEM of 3 to 8 independent experiments in triplicate wells for each construct. (C) Cells were
transfected with 0.5mg of luciferase plasmid bearing cPLA2a gene promoter by lipofection, incubated for 6h and then infected with adenovirus
carrying GFP-Sp1 (Ad-GFP-Sp1) at 50MOI. Cells infected with Ad-GFP were used as control. The luciferase activities and protein concentrations
were determined. The results shown represent the means SEM of three determinations. Cell lysates were prepared and DNA aﬃnity precipitation
assay was performed as described under Materials and Methods section. Binding of Sp1 and phospho-c-Jun (Ser73) to cPLA2a Sp1 probes was
analyzed by western blot.
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C/EBP a/b binding sites on the promoter region
(Figure 6A). No change of luciferase activity was observed
in nucleolin knockdown cells (Figure 6C), indicating
that nucleolin had no eﬀect on the SV40 promoter activity
and mRNA stability of the luciferase gene. The expres-
sion of luciferase gene was inhibited in c-Jun siRNA
oligonucleotides-transfected cells (Figure 6C). Since
nucleolin had no eﬀect on the mRNA stability of
luciferase gene, together with the reporter assay from
Figure 5A, these results indicated that nucleolin was
involved in the PMA-induced transcriptional activation of
cPLA2a gene. To further study whether nucleolin could
also play a function in post-transcriptional activation, we
used UTR-1-446 vector, containing SV40 promoter and
luciferase cDNA followed by cPLA2a 30UTR sequence
(Figure 6B) to dissect the requirement of 30UTR sequence
responsible for nucleolin-regulated mRNA stability. As
shown in Figure 6D, nucleolin siRNA signiﬁcantly
reduced luciferase activity, indicating nucleolin was
involved in the regulation of cPLA2a mRNA stability.
In addition, PMA had no eﬀect on UTR-1-446 luciferase
activity (Figure 6D), indicating that cPLA2a 30UTR
sequence was not essential for PMA-regulated cPLA2a
gene expression. These results revealed that PMA
regulated cPLA2a expression by favoring transcriptional
activation pathway but not through mRNA stabilization.
However, nucleolin contributed to not only PMA-
induced transcriptional activation of cPLA2a gene but
also stabilization of cPLA2a mRNA in cells without PMA
treatment.
Nucleolin and Sp1areindividually essentialfor the
recruitment of c-Junto GC-rich promoter
Several lines of evidence reveal that the motif
(U/G)CCCG(A/G) is important for nucleolin RNA
binding (39). However, it is interesting to note that
cPLA2a promoter, containing two potential Sp1-binding
sequences, AGCCCA and AGCCCCT might also be
considered as the nucleolin recognition element. We then
clariﬁed whether the binding of nucleolin to cPLA2a
promoter was Sp1-dependent. In Sp1 knockdown cells
(Figure 7A), the amount of c-Jun on DNA was reduced to
50% (Figure 7B). However, Sp1 siRNA had no signiﬁcant
eﬀect on the binding of nucleolin to DNA. We further
studied whether nucleolin was required for Sp1–DNA
interaction. Although the interaction of Sp1 with DNA
was not changed in nucleolin siRNA-treated cells, the
binding of c-Jun to DNA was almost abolished
(Figure 7B). To clarify that whether nucleolin bound to
DNA through Sp1-binding sites, we studied the binding of
nucleolin to wild-type Sp1 probes, compared to mutated
probes. As shown in Figure 7C, mutated Sp1 probes
abolished both bindings of Sp1 and nucleolin to DNA,
resulting in complete inhibition of the interaction between
c-Jun and DNA. These results indicated that the bindings
of nucleolin and Sp1 to DNA were independent of each
other. Furthermore, in addition to Sp1, nucleolin might
also be an anchor protein to recruit c-Jun to Sp1 sites and
activated cPLA2a gene expression in PMA-treated cells.
In order to further dissect that whether the binding of
nucleolin to Sp1 site was mediated by recognizing the
canonical or non-canonical Sp1 sequence, the promoters
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Figure 3. Eﬀect of c-Jun on PMA-induced expression of cPLA2a in A549 cells. (A) Cells were transfected with c-Jun siRNA oligonucleotide by
lipofection, incubated for 6h and then transfected with 0.5mg of pPLA 599. Cells were incubated for 24h and then treated with 5nM PMA for 18h.
The luciferase activities and protein concentrations were determined and normalized. The results shown represent the means SEM of three
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antibodies, respectively. SC: scramble oligonucleotides. Statistical signiﬁcance (
   P<0.001) between PMA with c-Jun siRNA and PMA alone was
analyzed by Student’s t-test. (B) Cells were transfected with 0.5mg of pRSVjun expression vector and 0.5mg of luciferase plasmid bearing cPLA2a
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ratio of pRSVjun treated to control cells is indicated. The results shown represent the means   SEM of 3 to 7 independent experiments in triplicate
wells for each construct.
222 Nucleic Acids Research, 2008, Vol. 36, No. 1with consensus Sp1 sequence of 12(S)-lipoxygenase (33)
and gastrin (40) or consensus Sp1 oligonucelotides were
used in DAPA. Although the binding of Sp1 to Sp1-
binding site was observed as expectations, the interaction
between nucleolin and DNA was only observed in cPLA2a
promoter, 12(S)-lipoxygenase promoter and consensus
Sp1 oligonucleotide. However, no interaction between
nucleolin and DNA was observed in gastrin promoter
or consensus NFkB site (Figure 7D). The binding of
phospho-c-Jun to DNA was increased in all oligonucleo-
tide probes in PMA-treated cells (Figure 7D). These
results revealed that not all the Sp1 or Sp1-like binding
sites were in favor of nucleolin binding, indicating that
the binding of nucleolin to Sp1 site was not determined
by canonical or non-canonical Sp1-binding sequence.
To further conﬁrm that nucleolin was essential for
c-Jun/Sp1-regulated gene expression resulted from the
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(A) Cells were starved for 18h in serum-free culture medium and then
treated with 5nM PMA for a diﬀerent time period as indicated. The
Sp1, nucleolin (NCL) and c-Jun proteins were detected by anti-Sp1,
anti-nucleolin and anti-c-Jun antibodies, respectively. (B and C)
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and DNA aﬃnity precipitation assay was performed as described under
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+19bp of cPLA2a promoter. Input: nonimmunoprecipitated cross-
linked chromatin.
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Figure 5. Eﬀect of nucleolin on PMA-induced expression of cPLA2a in
A549 cells. (A) Cells were transfected with nucleolin siRNA oligonu-
cleotide (siNCL) by lipofection, incubated for 6h and then transfected
with 0.5mg of pPLA 599 again. Cells were incubated for 24h and then
treated with 5nM PMA for 18h. The luciferase activities and protein
concentrations were determined and normalized. The results shown
represent the means SEM of three determinations. Expressions of
nucleolin, cPLA2a and b-actin proteins were analyzed by western blot
analysis using anti-nucleolin, cPLA2a and b-actin antibodies, respec-
tively. SC: scramble oligonucleotides. Statistical signiﬁcance (
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and
   P<0.001) between PMA with nucleolin siRNA and PMA alone
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Nucleic Acids Research,2008, Vol. 36,No. 1 223recruitment of c-Jun to Sp1 sites-dependent transcrip-
tional activation, we studied the eﬀect of nucleolin on the
induction of 12(S)-lipoxygenase which is Sp1-dependent,
and cyclooxygenase-2 which is Sp1-independent in cells
under EGF treatment (33,34). Under these experimental
conditions, c-Jun is essential for the EGF-induced
expression of 12(S)-lipoxygenase and cyclooxygenase-2.
Consistent with that observed in the regulation of cPLA2a
gene, nucleolin siRNA abolished the EGF-induced
transcriptional activation of 12(S)-lipoxygenase gene
(Figure 8A). Contrary to c-Jun/Sp1-regulated genes,
nucleolin was not involved in EGF-induced transcrip-
tional activation of cyclooxygenase-2 gene (Figure 8B).
DISCUSSION
The expression of cPLA2 can be regulated in NSCLC (7)
and is critical for transformed growth of NSCLC. When
these cells are treated with a speciﬁc inhibitor of the
enzyme, or blocking downstream production of prosta-
glandins with cyclooxygenase inhibitors, resulting in
inhibition of anchorage-independent growth of these
cells (7). These results suggest that induction of cPLA2 is
critical for tumorigenesis. Consistent with this ﬁnding,
lung tumorigenesis is inhibited in mice that are deﬁcient in
cPLA2 (41). In this study, we ﬁrst found that PMA
induced gene expression of cPLA2a in NSCLC. It has
been known that PMA-activated PKC signal transduction
pathway is thought to be involved in the oncogene
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(C) and UTR-1-446 (D) vectors. Cells were incubated for 24h and then
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performed as described under Materials and Methods section. Binding
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Activation of PKC with PMA impairs progression of lung
adenocarcinoma cells from early G1 phase into S phase
(42). The broad-range PKC inhibitor staurosporine
analog, PKC 412, induces apoptosis in SCLC cells and
sensitizes NSCLC cells to apoptosis induced by DNA-
damaging agents (43). Taking these results together,
we concluded that PMA-induced expression of cPLA2a
might be related to either a cause or a consequence of
PMA-regulated tumorigenesis of NSCLC.
In the regulation of gene expression, previous studies
have reported that c-Jun/Sp1 complex is critical for
various diﬀerent gene expressions, e.g. 12(S)-lipoxygenase,
keratin 16, p21
WAF1/CIP1 and neuronal nicotinic acetylcho-
line receptor b4 (26–29). Although overexpression of c-Jun
and Sp1 produces a synergistic increase in the rat cPLA2
promoter activity, no evidence shows that the formation
of c-Jun/Sp1 complex and the complex binding to the rat
cPLA2 promoter are observed (23). However, we ﬁrst
clariﬁed that PMA induced c-Jun/Sp1 interaction and the
complex bound to Sp1-binding sites of human cPLA2a
promoter, resulting in the induction of transcriptional
activation. In addition, we found that nucleolin was also
a coactivator interacting with c-Jun to regulate PMA-
induced transcription of cPLA2a gene. Nucleolin is a
ubiquitous, nonhistone nucleolar phosphoprotein of
exponentially growing eukaryotic cells, which is directly
involved in the regulation of ribosome biogenesis, the
processing of ribosomal RNA, mRNA stability, transcrip-
tional regulation and cell proliferation, and it is also a
downstream target of several signal transduction path-
ways (30). Matching our results, the functional role of
nucleolin involved in the transcriptional activation of gene
expression has been found. Nucleolin binds acetylated
interferon regulatory factor-2 (IRF-2) to enhance H4
promoter activity (44) and plays as a key activator of
HPV18 oncogene transcription in cervical cancer (45).
Nucleolin also binds transcription factors Myb and tumor
suppressor Rb to regulate Myb transcriptional activity
and tumor development (46,47). These ﬁndings suggest
that nucleolin may act as a transcriptional regulator via
interacting with activators. Indeed, in the experiments of
immunoprecipitation and DAPA, we found that nucleolin
bound and bridged c-Jun to Sp1-binding sites of cPLA2a
promoter (Figures 4C and 7B). These results suggested the
possibility that nucleolin participated in the regulation
of c-Jun/Sp1-regulated genes, e.g. 12(S)-lipoxygenase
(Figure 7D) and p21
WAF1/CIP1 to regulate cell growth
(48). From our study, we can conclude that for PMA-
induced cPLA2a gene expression, and nucleolin acts as a
coactivator via cooperation of c-Jun transcriptional
factor. However, the nucleolin/c-Jun complex had no
eﬀect on AP1-regulated promoter activation (Figures 6C
and 8B). The diﬀerent binding aﬃnity between nucleolin/
c-Jun to Sp1-binding site and to AP1-binding site might be
caused by the stereo-recognition of complex to the Sp1
binding but not AP1-binding sequences. Consistent with
the role of nucleolin in the regulation of mRNA stability,
we found that nucleolin also contributed to the stabiliza-
tion of cPLA2a mRNA. Since without identical nucleolin-
binding site UCCCGA but with HuR-binding element
AUUUA is found within the cPLA2a 30UTR sequence,
the eﬀect of nucleolin on the stabilization of cPLA2a
mRNA might result from the cooperation of nucleolin
with RNA-binding proteins as well as the basal expression
of GADD45a mRNA is regulated by association of
nucleolin and HuR (49). Indeed, we found that RNA-
binding protein HuR bound to AUUUA of cPLA2a
30UTR sequence and enhanced the mRNA stability (our
unpublished data). Although PMA had no eﬀect on the
stabilization of cPLA2a mRNA, our data showed that
nucleolin was also involved in the regulation of PMA-
induced transcriptional activation of cPLA2a gene. These
results revealed that nucleolin plays dual functions of
transcriptional and post-transcriptional activity in the
regulation of cPLA2a gene.
It is known that the motif (U/G)CCCG(A/G) is
responsible for the binding of nucleolin to RNA (39).
However, we found that the binding of nucleolin to the
GC-rich Sp1 site within cPLA2a promoter was in an Sp1-
independent manner. Thus, nucleolin might gain access to
DNA through two pathways. First, since Sp1 siRNA had
no eﬀect on the binding of nucleolin to Sp1 element,
indicating that nucleolin might directly bind to DNA and
recruit c-Jun transcriptional factor to Sp1 sites and then
activate gene expression. Nucleolin is a matrix attachment
region (MAR)-binding protein to provide a link between
DNA and nuclear matrix scaﬀolding (50). In addition,
nucleolin was also found to bind to the NFkB DNA-
binding motif and the KLF2 promoter (51,52). Thus,
nucleolin may interact with DNA and other transcrip-
tional factors, such as c-Jun, to regulate transcription. It is
very interesting to note that whether the binding of
nucleolin to GC-rich Sp1 site has the sequence speciﬁcity.
Contrary to the binding of nucleolin to cPLA2a promoter,
we found that SV40 promoter containing Sp1-binding
sites was not regulated by nucleolin. Furthermore, we also
found that the interaction between nucleolin and Sp1-
binding site was not occurred in all Sp1-regulated
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Figure 8. Nucelolin is essential for c-Jun/Sp1-regulated gene expression.
(A and B) A431 cells were transfected with nucleolin siRNA
oligonucleotides by lipofection, incubated for 6h and then transfected
with 0.5mg of pXLO-7-1 (A) and pXC918 (B) vectors bearing the
12(S)-lipoxygenase and cyclooxygenase-2 promoters, respectively. Cells
were incubated for 24h and pXLO-7-1- and pXC918-transfected cells
were treated with EGF (50ng/ml) for 18 and 6h, respectively. The
luciferase activities and protein concentrations were determined and
normalized. The results shown represent the means SEM of three
determinations. SC: scramble oligonucleotides. Statistical signiﬁcance
(
   P<0.001) between EGF with nucleolin siRNA and EGF alone was
analyzed by Student’s t-test.
Nucleic Acids Research,2008, Vol. 36,No. 1 225promoters such as gastrin. It is possible that the nucleotide
sequence surrounding the AGCCC and UCCCGA can
modulate the interaction of nucleolin with DNA and
RNA (39), respectively. Second, access of nucleolin to
cPLA2a promoter may also skip from direct binding but
be bridged by other factors to DNA. Although there was
no eﬀect of Sp1 siRNA on nucleolin binding, we could not
rule out the possibility that the binding of nucleolin to
DNA might have occurred concomitant with Sp1-like
proteins binding. In addition, in spite of nucleolin and Sp1
bound to DNA was dependent on Sp1-binding sites, the
binding of Sp1 to DNA was in a nucleolin-independent
manner. These results suggested that Sp1/c-Jun and
nucleolin/c-Jun complexes could together or indepen-
dently bind to Sp1-binding sites and regulate PMA-
induced transcriptional activation of cPLA2a gene.
In conclusion, we have identiﬁed the functional
interaction between c-Jun, nucleolin and Sp1 to mediate
cPLA2a expression in PMA signal-activated human tumor
cells. Our results demonstrate that the activation of the
PMA signaling pathway leads to the binding of c-Jun/
nucleolin and c-Jun/Sp1 complexes to the cPLA2a
promoter, resulting in the transcriptional activation of
cPLA2a gene. Based on the expression of cPLA2a is
critical for transformed growth of NSCLC and tumor-
igenesis (7,41), our study suggested that nucleolin, in
addition to contribute to the process of tumor develop-
ment by linking to major tumor suppressors, Rb and p53
(47,53), could associate with transcription factor c-Jun
and up-regulate cPLA2a expression to increase lipid
mediators, resulting in the tumorigenesis. Our data also
suggested that nucleolin binds to GC-rich elements. It is
likely that nucleolin binding at place of Sp1-binding
sequences could also mediate the expression of c-Jun/Sp1-
activated genes.
ACKNOWLEDGEMENTS
We are greatly indebted to Dr Jan-Jong Hung for
providing adenovirus carrying GFP-Sp1 and GFP con-
trol. This work was supported in part by grant NSC 95-
2320-B-006-071-MY2 from the National Science Council
of the Republic of China, and National Cheng Kung
University Project of Promoting Academic Excellence and
Developing World Class Research Centers. Funding to
pay the Open Access publication charges for this article
was provided by National Science Council of the Republic
of China.
Conﬂict of interest statement. None declared.
REFERENCES
1. Nie,D. and Honn,K.V. (2002) Cyclooxygenase, lipoxygenase and
tumor angiogenesis. Cell. Mol. Life Sci., 59, 799–807.
2. Cabral,G.A. (2005) Lipids as bioeﬀectors in the immune system.
Life Sci., 77, 1699–1710.
3. Bogatcheva,N.V., Sergeeva,M.G., Dudek,S.M. and Verin,A.D.
(2005) Arachidonic acid cascade in endothelial pathobiology.
Microvasc. Res., 69, 107–127.
4. Xu,X.C. (2002) COX-2 inhibitors in cancer treatment and preven-
tion, a recent development. Anticancer Drugs, 13, 127–137.
5. Hubbard,W.C., Alley,M.C., McLemore,T.L. and Boyd,M.R. (1988)
Proﬁles of prostaglandin biosynthesis in sixteen established cell lines
derived from human lung, colon, prostate, and ovarian tumors.
Cancer Res., 48, 4770–4775.
6. McLemore,T.L., Hubbard,W.C., Litterst,C.L., Liu,M.C., Miller,S.,
McMahon,N.A., Eggleston,J.C. and Boyd,M.R. (1988) Proﬁles of
prostaglandin biosynthesis in normal lung and tumor tissue from
lung cancer patients. Cancer Res., 48, 3140–3147.
7. Heasley,L.E., Thaler,S., Nicks,M., Price,B., Skorecki,K. and
Nemenoﬀ,R.A. (1997) Induction of cytosolic phospholipase A2 by
oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem.,
272, 14501–14504.
8. Leslie,C.C. (1997) Properties and regulation of cytosolic
phospholipase A2. J. Biol. Chem., 272, 16709–16712.
9. Evans,J.H., Spencer,D.M., Zweifach,A. and Leslie,C.C. (2001)
Intracellular calcium signals regulating cytosolic phospholipase
A2 translocation to internal membranes. J. Biol. Chem., 276,
30150–30160.
10. Hirabayashi,T., Kume,K., Hirose,K., Yokomizo,T., Iino,M.,
Itoh,H. and Shimizu,T. (1999) Critical duration of intracellular
Ca2+ response required for continuous translocation and activa-
tion ofcytosolic phospholipase A2. J. Biol. Chem., 274, 5163–5169.
11. Gijon,M.A., Spencer,D.M., Siddiqi,A.R., Bonventre,J.V. and
Leslie,C.C. (2000) Cytosolic phospholipase A2 is required for
macrophage arachidonic acid release by agonists that Do and Do
not mobilize calcium. Novel role of mitogen-activated protein
kinase pathways in cytosolic phospholipase A2 regulation. J. Biol.
Chem., 275, 20146–20156.
12. Qiu,Z.-H., Gijon,M.A., de Carvalho,M.S., Spencer,D.M. and
Leslie,C.C. (1998) The role of calcium and phosphorylation of
cytosolic phospholipase A2 in regulating arachidonic acid release in
macrophages. J. Biol. Chem., 273, 8203–8211.
13. You,H.J., Woo,C.-H., Choi,E.-Y., Cho,S.-H., Yoo,Y.J. and
Kim,J.-H. (2005) Roles of Rac and p38 kinase in the activation of
cytosolic phospholipase A2 in response to PMA. Biochem. J., 388,
527–535.
14. Lin,L.-L., Wartmann,M., Lin,A.Y., Knopf,J.L., Seth,A. and
Davis,R.J. (1993) cPLA2 is phosphorylated and activated by MAP
kinase. Cell, 72, 269–278.
15. Hefner,Y., Borsch-Haubold,A.G., Murakami,M., Wilde,J.I.,
Pasquet,S., Schieltz,D., Ghomashchi,F., Yates,J.R.III,
Armstrong,C.G. et al. (2000) Serine 727 phosphorylation and
activation of cytosolic phospholipase A2 by MNK1-related protein
kinases. J. Biol. Chem., 275, 37542–37551.
16. Muthalif,M.M., Hefner,Y., Canaan,S., Harper,J., Zhou,H.,
Parmentier,J.-H., Aebersold,R., Gelb,M.H. and Malik,K.U. (2001)
Functional interaction of calcium-/calmodulin-dependent protein
kinase II and cytosolic phospholipase A2. J. Biol. Chem., 276,
39653–39660.
17. Roshak,A.K., Jackson,J.R., McGough,K., Chabot-Fletcher,M.,
Mochan,E. and Marshall,L.A. (1996) Manipulation of distinct
NFkappa B proteins alters interleukin-1beta -induced human
rheumatoid synovial ﬁbroblast prostaglandin E2 formation. J. Biol.
Chem., 271, 31496–31501.
18. Wu,T., lkezono,T., Angus,C.W. and Shelhamer,J.H. (1994)
Characterization of the promoter for the human 85kDa cytosolic
phospholipase A2 gene. Nucleic Acids Res., 22, 5093–5098.
19. Dronadula,N., Liu,Z., Wang,C., Cao,H. and Rao,G.N. (2005)
STAT-3-dependent cytosolic phospholipase A2 expression is
required for thrombin-induced vascular smooth muscle cell motility.
J. Biol. Chem., 280, 3112–3120.
20. Neeli,I., Liu,Z., Dronadula,N., Ma,Z.A. and Rao,G.N. (2004) An
essential role of the Jak-2/STAT-3/cytosolic phospholipase A2 axis
in platelet-derived growth factor BB-induced vascular smooth
muscle cell motility. J. Biol. Chem., 279, 46122–46128.
21. Dolan-O’Keefe,M., Chow,V., Monnier,J., Visner,G.A. and
Nick,H.S. (2000) Transcriptional regulation and structural
organization of the human cytosolic phospholipase A2 gene.
Am. J. Physiol. Lung Cell Mol. Physiol., 278, L649–L657.
22. Tay,A., Maxwell,P., Li,Z., Goldberg,H. and Skorecki,K. (1994)
Isolation of promoter for cytosolic phospholipase A2 (cPLA2).
Biochim. Biophys. Acta, 1217, 345–347.
23. Blaine,S.A., Wick,M., Dessev,C. and Nemenoﬀ,R.A. (2001)
Induction of cPLA2 in lung epithelial cells and non-small cell lung
226 Nucleic Acids Research, 2008, Vol. 36, No. 1cancer is mediated by Sp1 and c-Jun. J. Biol. Chem., 276,
42737–42743.
24. Van Putten,V., Refaat,Z., Dessev,C., Blaine,S., Wick,M.,
Butterﬁeld,L., Han,S.-Y., Heasley,L.E. and Nemenoﬀ,R.A. (2001)
Induction of cytosolic phospholipase A2 by oncogenic Ras is
mediated through the JNK and ERK pathways in rat epithelial
cells. J. Biol. Chem., 276, 1226–1232.
25. Wick,M.J., Blaine,S., Van Putten,V., Saavedra,M. and
Nemenoﬀ,R.A. (2005) Lung Kruppel-like factor (LKLF) is a
transcriptional activator of the cytosolic phospholipase A2 alpha
promoter. Biochem. J., 387, 239–246.
26. Chen,B.K. and Chang,W.C. (2000) Functional interaction between
c-Jun and promoter factor Sp1 in epidermal growth factor-induced
gene expression of human 12(S)-lipoxygenase. Proc. Natl Acad. Sci.
USA, 97, 10406–10411.
27. Wang,Y.N. and Chang,W.C. (2003) Induction of disease-associated
keratin 16 gene expression by epidermal growth factor is regulated
through cooperation of transcription factors Sp1 and c-Jun. J. Biol.
Chem., 278, 45848–45857.
28. Kardassis,D., Papakosta,P., Pardali,K. and Moustakas,A. (1999)
c-Jun transactivates the promoter of the human p21WAF1/Cip1
gene by acting as a superactivator of the ubiquitous transcription
factor Sp1. J. Biol. Chem., 274, 29572–29581.
29. Melnikova,I.N. and Gardner,P.D. (2001) The signal transduction
pathway underlying ion channel gene regulation by Sp1-c-Jun
interactions. J. Biol. Chem., 276, 19040–19045.
30. Srivastava,M. and Pollard,H.B. (1999) Molecular dissection of
nucleolin’s role in growth and cell proliferation: new insights.
FASEB J., 13, 1911–1922.
31. Hanakahi,L.A., Dempsey,L.A., Li,M.-J. and Maizels,N. (1997)
Nucleolin is one component of the B cell-speciﬁc transcription
factor and switch region binding protein, LR1. Proc. Natl Acad.
Sci. USA, 94, 3605–3610.
32. Chen,B.K., Kung,H.C., Tsai,T.Y. and Chang,W.C. (2000) Essential
role of mitogen-activated protein kinase pathway and c-Jun
induction in epidermal growth factor-induced gene expression of
human 12-lipoxygenase. Mol. Pharmacol., 57, 153–161.
33. Liu,Y.W., Arakawa,T., Yamamoto,S. and Chang,W.C. (1997)
Transcriptional activation of human 12-lipoxygenase gene promoter
is mediated through Sp1 consensus sites in A431 cells. Biochem. J.,
324, 133–140.
34. Chen,L.C., Chen,B.K. and Chang,W.-C. (2005) Activating protein
1-mediated cyclooxygenase-2 expression is independent of N-
terminal phosphorylation of c-Jun. Mol. Pharmacol., 67, 2057–2069.
35. Zhu,Y., Saunders,M.A., Yeh,H., Deng,W.-G. and Wu,K.K. (2002)
Dynamic regulation of cyclooxygenase-2 promoter activity by
isoforms of CCAAT/enhancer-binding proteins. J. Biol. Chem., 277,
6923–6928.
36. Saccani,S., Pantano,S. and Natoli,G. (2001) Two waves of nuclear
factor kappaB recruitment to target promoters. J. Exp. Med., 193,
1351–1360.
37. Andrews,N.C. and Faller,D.V. (1991) A rapid micropreparation
technique for extraction of DNA-binding proteins from limiting
numbers of mammalian cells. Nucleic Acids Res., 19, 2499.
38. Tay,A., Maxwell,P., Li,Z.-G., Goldberg,H. and Skorecki,K. (1994)
Cytosolic phospholipase A2 gene expression in rat mesangial
cells is regulated post-transcriptionally. Biochem. J., 304, 417–422.
39. Ghisolﬁ-Nieto,L., Joseph,G., Puvion-Dutilleul,F., Amalric,F. and
Bouvet,P. (1996) Nucleolin is a sequence-speciﬁc RNA-binding
protein: characterization of targets on pre-ribosomal RNA. J. Mol.
Biol., 260, 34–53.
40. Hansen,T.V.O., Bundgaard,J.R., Nielsen,F.C. and Rehfeld,J.F.
(1999) Composite action of three GC/GT boxes in the proximal
promoter region is important for gastrin gene transcription. Mol.
Cell. Endocrinol., 155, 1–8.
41. Meyer,A.M., Dwyer-Nield,L.D., Hurteau,G.J., Keith,R.L.,
O’Leary,E., You,M., Bonventre,J.V., Nemenoﬀ,R.A. and
Malkinson,A.M. (2004) Decreased lung tumorigenesis in mice
genetically deﬁcient in cytosolic phospholipase A2. Carcinogenesis,
25, 1517–1524.
42. Nakagawa,M., Oliva,J.L., Kothapalli,D., Fournier,A.,
Assoian,R.K. and Kazanietz,M.G. (2005) Phorbol ester-induced G1
phase arrest selectively mediated by protein kinase C-delta-
dependent induction of p21. J. Biol. Chem., 280, 33926–33934.
43. Hemstrom,T.H., Joseph,B., Schulte,G., Lewensohn,R. and
Zhivotovsky,B. (2005) PKC 412 sensitizes U1810 non-
small cell lung cancer cells to DNA damage. Exp. Cell Res., 305,
200–213.
44. Masumi,A., Fukazawa,H., Shimazu,T., Yoshida,M., Ozato,K.,
Komuro,K. and Yamaguchi,K. (2006) Nucleolin is involved in
interferon regulatory factor-2-dependent transcriptional activation.
Oncogene, 25, 5113–5124.
45. Grinstein,E., Wernet,P., Snijders,P.J.F., Rosl,F., Weinert,I., Jia,W.,
Kraft,R., Schewe,C., Schwabe,M. et al. (2002) Nucleolin as
activator of human papillomavirus type 18 oncogene transcription
in cervical cancer. J. Exp. Med., 196, 1067–1078.
46. Ying,G.-G., Proost,P., van Damme,J., Bruschi,M., Introna,M. and
Golay,J. (2000) Nucleolin, a novel partner for the Myb
transcription factor family that regulates their activity. J. Biol.
Chem., 275, 4152–4158.
47. Grinstein,E., Shan,Y., Karawajew,L., Snijders,P.J.F.,
Meijer,C.J.L.M., Royer,H.-D. and Wernet,P. (2006) Cell
cycle-controlled interaction of nucleolin with the retinoblastoma
protein and cancerous cell transformation. J. Biol. Chem., 281,
22223–22235.
48. Saxena,A., Rorie,C.J., Dimitrova,D., Daniely,Y. and Borowiec,J.A.
(2006) Nucleolin inhibits Hdm2 by multiple pathways leading to
p53 stabilization. Oncogene, 25, 7274–7288.
49. Zhang,Y., Bhatia,D., Xia,H., Castranova,V., Shi,X. and Chen,F.
(2006) Nucleolin links to arsenic-induced stabilization of GADD45a
mRNA. Nucleic Acids Res., 34, 485–495.
50. Dickinson,L.A. and Kohwi-Shigematsu,T. (1995) Nucleolin is a
matrix attachment region DNA-binding protein that speciﬁcally
recognizes a region with high base-unpairing potential. Mol. Cell.
Biol., 15, 456–465.
51. Embree-Ku,M. and Gruppuso,P.A. (2005) The role of nuclear
factor kB in late-gestation liver development in the rat. Hepatology,
42, 326–334.
52. Huddleson,J.P., Ahmad,N. and Lingrel,J.B. (2006) Up-regulation of
the KLF2 transcription factor by ﬂuid shear stress requires
nucleolin. J. Biol. Chem., 281, 15121–15128.
53. Daniely,Y., Dimitrova,D.D. and Borowiec,J.A. (2002) Stress-
dependent nucleolin mobilization mediated by p53-nucleolin
complex formation. Mol. Cell. Biol., 22, 6014–6022.
Nucleic Acids Research,2008, Vol. 36,No. 1 227